Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Introduction to Fibroblasts
Mitogens and the Cell Cycle
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response.
Junquan Song1,2, Rongyuan Wei1,2, Chenchen Liu1,2
1Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
View abstract on PubMed
Antigen-presenting cancer-associated fibroblasts (apCAFs) boost T cell immunity in gastric cancer. These apCAFs may predict immunotherapy response across multiple cancer types.
More Related Videos
08:02Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
10:26Assessment of Mitochondrial Health in Cancer-Associated Fibroblasts Isolated from 3D Multicellular Lung Tumor Spheroids
Published on: October 21, 2022
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Cancer-associated fibroblasts (CAFs) are key players in tumor progression and immune modulation.
- The functional diversity within CAFs is not fully understood, particularly in gastric cancer (GC).
Purpose of the Study:
- To identify and characterize distinct CAF subsets in gastric cancer.
- To investigate the role of antigen-presenting CAFs (apCAFs) in anti-tumor immunity.
- To explore the potential of apCAFs as biomarkers for immunotherapy response.
Main Methods:
- Identification of apCAFs based on high MHC II expression in GC tumors.
- In vivo and in vitro experiments to assess apCAF function on T cells and macrophages.
- Analysis of apCAF infiltration in tumors from immunotherapy responders across different cancer types.
Main Results:
- Antigen-presenting CAFs (apCAFs) were identified in GC, predominantly near tertiary lymphoid structures.
- apCAFs enhance T cell activation, proliferation, and cytotoxic capacity, bolstering anti-tumor immunity.
- apCAFs promote pro-inflammatory macrophage polarization, creating a positive feedback loop that amplifies immune responses.
- Higher apCAF infiltration correlates with immunotherapy response in various cancers.
Conclusions:
- This study elucidates CAF heterogeneity in GC, identifying apCAFs as crucial immune modulators.
- apCAFs represent a promising pan-cancer biomarker for predicting immunotherapy efficacy.
- Targeting apCAFs could be a therapeutic strategy to enhance anti-tumor immunity.
